Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AB, absolute, accommodate, acetaminophen, aimed, algorithm, Annex, Arbitrage, Asia, attend, augment, begun, Beijing, benign, breach, campaign, cardiovascular, categorization, certified, cessation, China, clarify, clock, commonly, configured, consortium, convene, correspondingly, counsel, count, coupled, CPA, cycle, defamed, denying, description, Designee, diameter, diminish, distributor, duty, education, educational, Elizabeth, endeavor, entail, exploring, fiduciary, fill, forecasted, Gen, Goldberg, graphical, Grid, hand, head, Hong, honoring, hypoglycemic, interference, introductory, Kong, launch, leveraged, lower, lowest, Macau, manual, MARD, marketplace, membership, Michael, minute, moderate, MTIA, mutual, NE, nominate, nominated, Nominating, numerical, oncology, panel, pilot, Pin, pivotal, poster, predicate, prejudice, prelaunch, put, quickly, recapitalization, recovering, referenced, registry, reorganization, Republic, restructuring, retroactively, Room, session, Shang, Sino, solicit, Specimen, split, stringent, SUD, surgery, surgical, symposia, Taiwan, target, targeted, Tau, Tech, theory, Tradeshow, TUV, uncover, undergone, unspecified, usability, usage, user, vacancy, verified, waiting, Washington, wife, workforce
Removed:
absorption, accept, acute, ADA, adding, administer, administered, afraid, agent, amenable, analyte, assembly, attempt, attributed, Aurora, bid, billion, biotechnology, Boenning, build, Burnham, cancer, carbohydrate, challenging, chemical, chemistry, chronic, comfort, commit, concentrated, content, cure, curing, dedicated, detailed, diagnosed, diet, dilutive, discovery, disease, division, dosage, doubtful, drastic, element, expanded, exposing, extending, extreme, fat, fifty, fluidity, goal, grow, guide, Hill, hormone, hypoglycemia, identity, IND, infrastructure, injectable, insufficiently, invasive, LifeTech, lipid, Monarch, national, NDA, nonirritating, nontoxic, nutrition, objective, OTC, OTCBB, outmost, overlap, owe, parenteral, permeability, pipeline, pocket, pool, population, positioned, preclude, preliminary, preserve, prevented, productivity, Project, properly, purity, qualifying, ranging, refuse, repaid, requesting, resistance, restrict, retail, round, Scattergood, sequential, serving, sharply, Sherbrooke, specific, strength, synergistic, systemic, systemically, tightening, tightly, tolerance, tooling, topically, treat, type, uncollectible, undelivered, unmet, unrelated, unwanted, utilizing, vested, viable
Filing tables
Filing exhibits
- 10-K Annual report
- 3.6 Certificate of Designation, Preferences and Rights of Series E Convertible Preferred Stock Dated December 10, 2013.
- 4.8 Form of Warrant to Purchase Common Stock Dated December 10, 2013.
- 10.31 License Development and Commercialization Agreement by and Between the Company and Medical Technologies Innovations Asia, LTD, Dated December 9, 2013
- 10.32 Securities Purchase Agreement by and Between the Company and Medical Technologies Innovations Asia, LTD and Beijing Sino Tau Shang Pin Tech and Development Corp., Dated December 10, 2013
- 10.33 Securities and Purchase Agreement by and Between the Company and Platinum Partners Value Arbitrage Fund L.P. and Platinum Partners Liquid Opportunity Master Fund L.P., Dated December 10, 2013
- 10.34 Second Amendment to the Consulting Agreement by and Between the Company and Robert F. Doman., Dated December 26, 2013
- 10.35 First Amendment to the Securities Purchase Agreement and License, Development and Commercialization Agreement by and Between the Company and Medical Technologies Innovations Asia, LTD and Beijing Sino Tau Shang Pin Tech, Dated January 30, 2014
- 21.1 Subsidiaries of the Company.
- 23.1 Consent of Wolf & Company, P.C., Independent Registered Public Accounting Firm.
- 31.1 Certification of Chief Executive Officer Pursuant to Rule 13A-14 (A) Under the Securities Exchange Act of 1934, As Amended, As Adopted Pursuant to Section 302 of the Sarbanes-oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer Pursuant to Rule 13A-14 (A) Under the Securities Exchange Act of 1934, As Amended, As Adopted Pursuant to Section 302 of the Sarbanes-oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002.
- Download Excel data file
- View Excel data file
ECTE similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Echo Therapeutics, Inc. (the “Company”) for the fiscal year ended December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher P. Schnittker, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Christopher P. Schnittker
Christopher P. Schnittker, C.P.A.
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
March 28, 2014